Acutaas Chemicals Ltd

Net profit of Acutaas Chemicals rose 140.18% to Rs 107.96 crore in the quarter ended December 2025 as against Rs 44.95 crore during the previous quarter ended December 2024. Sales rose 42.98% to Rs 393.18 crore in the quarter ended December 2025 as against Rs 274.99 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales393.18274.99 43 OPM %38.3224.97 - PBDT154.4969.65 122 PBT144.6763.33 128 NP107.9644.95 140 Powered by Capital Market - Live

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live

Net profit of Acutaas Chemicals rose 93.52% to Rs 72.24 crore in the quarter ended September 2025 as against Rs 37.33 crore during the previous quarter ended September 2024. Sales rose 24.10% to Rs 306.20 crore in the quarter ended September 2025 as against Rs 246.73 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales306.20246.73 24 OPM %31.1319.83 - PBDT104.5856.87 84 PBT96.1850.04 92 NP72.2437.33 94 Powered by Capital Market - Live

Profit before tax (PBT) soared 92.19% YoY to Rs 96.17 crore in Q2 FY26. In Q2 FY26, EBITDA jumped 94.8% to Rs 953 crore compared with Rs 489 core in Q2 FY25. EBITDA margin increased 31.1% in Q2 FY26 as against 19.8% in Q2 FY25. Naresh Patel, executive chairman & managing director, Acutaas Chemicals, said: 'Our focus has always been on building a long-term, sustainable business rather than chasing short-term opportunities. This disciplined approach is now yielding tangible results as we strengthen global partnerships and expand into new growth verticals such as Battery Chemicals and Semiconductors. In Q2 FY26, our revenue grew by 24.1% year-on-year to Rs 306.2 crore, driven by strong performance in Advanced Pharmaceutical Intermediates and stable contributions from Specialty Chemicals. We remain confident of delivering around 25% revenue growth for the full year, backed by a resilient business foundation and clear strategic direction.' Acutaas Chemicals is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. The scrip hit all-time high at Rs 1649.60 in intraday today.Powered by Capital Market - Live

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 17 October 2025.Powered by Capital Market - Live

Acutaas Chemicals announced that the Annual General Meeting(AGM) of the company will be held on 25 September 2025.Powered by Capital Market - Live

In Q1 FY26, Acutaas Chemicals reported a 17.3% rise in consolidated revenue from operations at Rs 207.2 crore, up from Rs 176.7 crore in Q1 FY25. Exports contributed 60% while the domestic business accounted for the remaining 40%. Gross profit surged 48.4% YoY to Rs 110.3 crore, expanding the gross margin from 42.1% to 53.2% in Q1 FY26. EBITDA grew 72.4% to Rs 50.9 crore, while net profit (PAT) soared to Rs 44 crore, a 199.6% jump over the same quarter last year. The PAT margin improved from 8.3% to 21.2% in Q1 FY26, reflecting strong operating efficiency. Exports contributed 60% and the domestic business accounting for the remaining 40%. On a sequential basis, performance moderated. The company's consolidated revenue declined 32.8% from Rs 308.5 crore in Q4 FY25. Gross profit dropped 24.4%, while EBITDA fell 40.1% and PAT slipped 29.8% from Q4 FY25. Still, profitability ratios held firm, with EBITDA margin at 24.6% and PAT margin at 21.2% in Q1 FY26, compared to 27.5% and 20.3%, respectively, in Q4 FY25. Both margins saw a sharp improvement from 16.7% EBITDA margin and 8.3% PAT margin in Q1 FY25. Naresh Patel, executive chairman & managing director, Acutaas Chemicals, said: I am happy to share that we've had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality. I am happy to announce that we have entered into a joint venture in South Korea which rings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across COMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins. Acutaas Chemicals (formerly Ami Organics) is a global manufacturer of advanced pharmaceutical intermediates and speciality chemicals. It serves a diverse set of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Powered by Capital Market - Live

Net profit of Acutaas Chemicals rose 217.49% to Rs 44.29 crore in the quarter ended June 2025 as against Rs 13.95 crore during the previous quarter ended June 2024. Sales rose 17.30% to Rs 207.24 crore in the quarter ended June 2025 as against Rs 176.67 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales207.24176.67 17 OPM %24.5716.71 - PBDT66.2126.13 153 PBT58.0819.95 191 NP44.2913.95 217 Powered by Capital Market - Live

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 30 July 2025.Powered by Capital Market - Live

Baba Advance Materials (BAML), a wholly owned subsidiary company of Acutaas Chemicals has entered into a joint venture agreement with J & Materials Co., a South Korean Company, whereby BAML shall hold 75% of the share capital of the joint venture company Indichem Inc. (JV Company) a South Korean Company and the remaining 25% of the share capital of the JV Company will be held by J & Materials Co. Powered by Capital Market - Live